• Record $21.3m quarterly revenue, up 137% vs prior corresponding period
• Record $20.9 million quarterly cash receipts, up 146% vs prior corresponding period
• FY26 Guidance: Revenue A$65-75m; Adjusted EBITDA A$16.5-19m

Bioxyne Limited (ASX: BXN), an Australian pharmaceutical company focused on the development manufacture and commercialisation of innovative medicines final patient dosage forms and active pharmaceutical ingredients, is pleased to report a record quarterly result for the period ending 31 March 2026. The result was driven by increased demand for the Company's GMP-manufactured medicinal cannabis, MDMA and psilocybin products across key international and domestic markets. European performance was a strong contributor, with UK and Europe/Germany revenues for the quarter at $2.4 million, a 34% increase over the prior quarter. New high-value contract wins with global partners, initial purchase orders for GMP-manufactured psilocybin capsules (BLSPSIL25), and positive regulatory tailwinds further supported the period's performance. Bioxyne Australia sustained its growth trajectory, recording increases across all product categories. White label manufacturing was a notable contributor both domestically and internationally, with growth in order volumes reflecting the expansion of existing customer relationships. Psychedelics continued to develop as an emerging and important health category, with increased supply and shipments of both MDMA and psilocybin to authorised prescriber and high-profile clinical trials across the country. The result also reflects the ongoing leverage of Bioxyne's integrated pharmaceutical manufacturing platform, with gains in manufacturing capacity and operational efficiency supporting the Company's ability to scale across its product portfolio.

FY26 Revenue A$65-75m; Adjusted EBITDA A$16.5-19m

Continued regulatory tailwinds in Australia, including potential reforms to driving laws relating to the use of medicinal cannabis, are expected to drive further domestic growth. Internationally, the ramp-up of supply into the UK and Germany, supported by the new GMP manufacturing facility in Scotland scheduled for completion by the end of 2026, positions Bioxyne for significant expansion. These markets are anticipated to substantially exceed the current Australian opportunity as the Company leverages its scalable, cash-flow positive platform and strong global partnerships.